Journal
BMC IMMUNOLOGY
Volume 16, Issue -, Pages -Publisher
BMC
DOI: 10.1186/s12865-015-0135-7
Keywords
-
Categories
Funding
- CHOA Center for Transplantation and Immune-mediated Disorders Pilot Grant
- ACTSI KL2-Mentored Clinical and Translational Research Program
- National Institutes of Health [KL2TR000455]
Ask authors/readers for more resources
Mesenchymal stromal cells (MSCs) are multipotent progenitor cells known to modulate the immune system and to promote hematopoiesis. These dual effects make MSCs attractive for use as cellular therapy in hematopoietic cell transplantation (HCT). MSCs can be used peri-HCT or pre-engraftment to modulate immune reconstitution, promoting hematopoietic stem cell (HSC) engraftment and/or preventing graft-versus-host disease (GVHD). Pre-clinical studies have demonstrated that MSCs can potentiate HSC engraftment and prevent GVHD in a variety of animal models. Clinical trials have been small and largely non-randomized but have established safety and early evidence of efficacy, supporting the need for larger randomized trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available